Search

Your search keyword '"Burmeister, Bryan H."' showing total 160 results
Start Over Author "Burmeister, Bryan H."
160 results on '"Burmeister, Bryan H."'

2. Utility of 30-day mortality as a quality metric for palliative radiation treatment: A population-based analysis from Queensland, Australia.

Author

Guan, Tracey L., Kutzko, Justin H., Lunn, Dominic P., Dunn, Nathan A. M., Burmeister, Bryan H., Dadwal, Parvati, Tran, Nancy, and Holt, Tanya R.

Subjects
PALLIATIVE treatment, PROPORTIONAL hazards models, MORTALITY, DEATH rate, LIFE expectancy
Abstract

Introduction: Palliative radiotherapy (PRT) is frequently used to treat symptoms of advanced cancer, however benefits are questionable when life expectancy is limited. The 30-day mortality rate after PRT is a potential quality indicator, and results from a recent meta-analysis suggest a benchmark of 16% as an upper limit. In this population-based study from Queensland, Australia, we examined 30-day mortality rates following PRT and factors associated with decreased life expectancy. Methods: Retrospective population data from Queensland Oncology Repository was used. Study population data included 22,501 patients diagnosed with an invasive cancer who died from any cause between 2008 and 2017 and had received PRT. Thirty-day mortality rates were determined from the date of last PRT fraction to date of death. Cox proportional hazards models were used to identify factors independently associated with risk of death within 30 days of PRT. Results: Overall 30-day mortality after PRT was 22.2% with decreasing trend in more recent years (P = 0.001). Male (HR = 1.20, 95% CI = 1.13–1.27); receiving 5 or less radiotherapy fractions (HR = 2.97, 95% CI = 2.74–3.22 and HR = 2.17, 95% CI = 2.03–2.32, respectively) and receiving PRT in a private compared to public facility (HR = 1.61, 95% CI = 1.51–1.71) was associated with decreased survival. Conclusion: The 30-day mortality rate in Queensland following PRT is higher than expected and there is scope to reduce unnecessarily protracted treatment schedules. We encourage other Australian and New Zealand centres to examine and report their own 30-day mortality rate following PRT and would support collaboration for 30-day mortality to become a national and international quality metric for radiation oncology centres. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan

Author

Lo, Serigne N., Hong, Angela M., Haydu, Lauren E., Ahmed, Tasnia, Paton, Elizabeth J., Steel, Victoria, Hruby, George, Tran, Anh, Morton, Rachael L., Nowak, Anna K., Vardy, Janette L., Drummond, Katharine J., Dhillon, Haryana M., Mandel, Catherine, Scolyer, Richard A., Middleton, Mark R., Burmeister, Bryan H., Thompson, John F., and Fogarty, Gerald B.

Published
2019
Full Text
View/download PDF

4. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

Author

Henderson, Michael A, Burmeister, Bryan H, Ainslie, Jill, Fisher, Richard, Di Iulio, Juliana, Smithers, B Mark, Hong, Angela, Shannon, Kerwin, Scolyer, Richard A, Carruthers, Scott, Coventry, Brendon J, Babington, Scott, Duprat, Joao, Hoekstra, Harald J, and Thompson, John F

Published
2015
Full Text
View/download PDF

6. Esophagus Carcinoma Surveillance Counterpoint: Australia

Author

Smithers, Bernard Mark, Thomas, Janine M., Burmeister, Bryan H., Johnson, Frank E., editor, Maehara, Yoshihiko, editor, Browman, George P., editor, Margenthaler, Julie A., editor, Audisio, Riccardo A., editor, Thompson, John F., editor, Johnson, David Y., editor, Earle, Craig C., editor, and Virgo, Katherine S., editor

Published
2013
Full Text
View/download PDF

8. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: A prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05)

Author

Ball, David L., Fisher, Richard J., Burmeister, Bryan H., Poulsen, Michael G., Graham, Peter H., Penniment, Michael G., Vinod, Shalini K., Krawitz, Hedley E., Joseph, David J., Wheeler, Greg C., and McClure, Bev E.

Published
2013
Full Text
View/download PDF

12. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction

Author

Faron, Matthieu, primary, Cheugoua-Zanetsie, Armel Maurice, additional, Thirion, Pierre, additional, Nankivell, Matthew, additional, Winter, Kathryn, additional, Cunningham, David, additional, Van der Gaast, Ate, additional, Law, Simon, additional, Langley, Ruth, additional, de Vathaire, Florent, additional, Valmasoni, Michele, additional, Mauer, Muriel, additional, Roth, Jack, additional, Gebski, Val, additional, Burmeister, Bryan H., additional, Paoletti, Xavier, additional, van Sandick, Johanna, additional, Fu, Jianhua, additional, Ducreux, Michel, additional, Blanchard, Pierre, additional, Tierney, Jayne, additional, Pignon, Jean-Pierre, additional, and Michiels, Stefan, additional

Published
2021
Full Text
View/download PDF

15. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery in esophageal or gastro-esophageal carcinoma.

Author

Faron, Matthieu, primary, Cheugoua-Zanetsie, Armel Maurice, additional, Nankivell, Matthew Guy, additional, Winter, Kathryn A., additional, Law, Simon, additional, van der Gaast, Ate Van Der, additional, Ychou, Marc, additional, Mauer, Murielle, additional, Valmasoni, Michele, additional, Roth, Jack A., additional, Blanchard, Pierre, additional, Thirion, Pierre Guillame, additional, Tierney, Jayne F., additional, Gebski, Val, additional, Burmeister, Bryan H., additional, Paoletti, Xavier, additional, Yang, Hong, additional, van Sandick, Johanna W., additional, Ducreux, Michel, additional, and Michiels, Stefan, additional

Published
2021
Full Text
View/download PDF

16. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction

Author

Faron, Matthieu, Cheugoua-Zanetsie, Armel Maurice, Thirion, Pierre, Nankivell, Matthew, Winter, Kathryn, Cunningham, David, van der Gaast, A. (Ate), Law, Simon, Langley, Ruth, de Vathaire, Florent, Valmasoni, Michele, Mauer, Muriel, Roth, Jack, Gebski, Val, Burmeister, Bryan H., Paoletti, Xavier, van Sandick, Johanna, Fu, Jianhua, Ducreux, Michel, Blanchard, Pierre, Tierney, Jayne, Pignon, Jean Pierre, Michiels, Stefan, Faron, Matthieu, Cheugoua-Zanetsie, Armel Maurice, Thirion, Pierre, Nankivell, Matthew, Winter, Kathryn, Cunningham, David, van der Gaast, A. (Ate), Law, Simon, Langley, Ruth, de Vathaire, Florent, Valmasoni, Michele, Mauer, Muriel, Roth, Jack, Gebski, Val, Burmeister, Bryan H., Paoletti, Xavier, van Sandick, Johanna, Fu, Jianhua, Ducreux, Michel, Blanchard, Pierre, Tierney, Jayne, Pignon, Jean Pierre, and Michiels, Stefan

Abstract

Introduction: Which neoadjuvant treatment for locally advanced thoracic oesophagus (TE) or gastro-oesophageal junction carcinoma is best remains an open question. Randomised controlled trials variously accrued patients with adenocarcinoma and squamous cell carcinoma, making strong conclusions hard to obtain. The primary objective of this individual participant data meta-analysis was to investigate the effect of neoadjuvant chemotherapy on overall survival (OS). Patients and methods: Eligible trials should have closed to accrual before 2016 and compared neoadjuvant chemotherapy and surgery (CS) to surgery alone. All relevant published and unpublished trials were identified via searches of electronic databases, conference proceedings and clinical trial registers. The main end-point was OS. Investigators were contacted to obtain the individual patient data, which was recorded, harmonised and checked. A random-effects Cox model, stratified by trial, was used for meta-analysis and subgroup analyses were preplanned. Results: 16 trials were identified as eligible. Individual patient data were obtained from 12 trial and 2478 patients. CS was associated with an improved OS versus surgery, hazard ratio (HR) = 0.83 [0.72–0.96], p < 0.0001, translating to an absolute benefit of 5.7% at 5-years from 16.8% to 22.5%. Treatment effects did not vary substantially between adenocarcinoma (HR = 0.73 [0.62–0.87]) and squamous cell carcinoma (HR = 0.91 [0.76–1.08], interaction p = 0.26). A somewhat more pronounced effect was observed in gastro-oesophageal junction (HR = 0.68 [0.50–0.93]) versus TE (HR = 0.87 [0.75–1.00], interaction p = 0.07). CS was also associated with a greater disease-free survival (HR = 0.74 [0.64–0.85], p < 0.001). Conclusions: Neoadjuvant chemotherapy conferred a better OS than surgery alone and should be considered in all anatomical location and histological subtypes.

Published
2021

27. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial

Author

Hong, Angela M., primary, Fogarty, Gerald B., additional, Dolven-Jacobsen, Kari, additional, Burmeister, Bryan H., additional, Lo, Serigne N., additional, Haydu, Lauren E., additional, Vardy, Janette L., additional, Nowak, Anna K., additional, Dhillon, Haryana M., additional, Ahmed, Tasnia, additional, Shivalingam, Brindha, additional, Long, Georgina V., additional, Menzies, Alexander M., additional, Hruby, George, additional, Drummond, Katharine J., additional, Mandel, Catherine, additional, Middleton, Mark R., additional, Reisse, Claudius H., additional, Paton, Elizabeth J., additional, Steel, Victoria, additional, Williams, Narelle C., additional, Scolyer, Richard A., additional, Morton, Rachael L., additional, and Thompson, John F., additional

Published
2019
Full Text
View/download PDF

32. Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).

Author

Fogarty, Gerald, primary, Dolven-Jacobsen, Kari, additional, Morton, Rachael L., additional, Hruby, George, additional, Nowak, Anna K., additional, Vardy, Janette L., additional, Drummond, Katharine J., additional, Dhillon, Haryana M., additional, Mandel, Catherine, additional, Scolyer, Richard A., additional, Shivalingham, Brindha, additional, Middleton, Mark R., additional, Burmeister, Bryan H., additional, Lo, Serigne, additional, Reisse, Claudius H., additional, Paton, Elizabeth J., additional, Steel, Victoria, additional, Williams, Narelle C., additional, Thompson, John F., additional, and Hong, Angela M., additional

Published
2019
Full Text
View/download PDF

33. Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus

Author

Visser, Els, Edholm, David, Smithers, B. Mark, Thomson, Iain G., Burmeister, Bryan H., Walpole, Euan T., Gotley, David C., Joubert, Warren L., Atkinson, Victoria, Mai, Tao, Thomas, Janine M., Barbour, Andrew P., Visser, Els, Edholm, David, Smithers, B. Mark, Thomson, Iain G., Burmeister, Bryan H., Walpole, Euan T., Gotley, David C., Joubert, Warren L., Atkinson, Victoria, Mai, Tao, Thomas, Janine M., and Barbour, Andrew P.

Abstract

BackgroundThe optimal treatment strategy for patients with esophageal adenocarcinoma (EAC) remains undetermined. This study compared outcomes in patients undergoing neoadjuvant chemotherapy (nCT) and neoadjuvant chemoradiotherapy (nCRT) for EAC. MethodsPatients who underwent nCT or nCRT followed by surgery for EAC were identified from a prospective database (2000-2017) and included. After propensity score matching, the impact of the treatments on postoperative complications, in-hospital mortality, pathological outcomes, and survival rates were compared. ResultsOf the 396 eligible patients, 262 patients were analysed following matching with 131 patients in both groups. There were no significant differences between the nCT and nCRT groups for overall complications (59% vs 57%, P=0.802) or in-hospital mortality (2% vs 0%, P=0.156). Patients who had nCRT had more R0 resections (93% vs 83%, P=0.013), and higher pathological complete response rates (15% vs 5%, P<0.001). No differences in 5-year overall survival rates (nCT vs nCRT; 44% vs 33%, P=0.645) were found. ConclusionIn this study no differences between nCT and nCRT were seen in postoperative complications and in-hospital mortality in patients treated for EAC. Inspite of improved complete resection and pathological response there was no difference in the overall survival between the treatment modalities.

Published
2018
Full Text
View/download PDF

36. Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus

Author

Visser, Els, primary, Edholm, David, additional, Smithers, B. Mark, additional, Thomson, Iain G., additional, Burmeister, Bryan H., additional, Walpole, Euan T., additional, Gotley, David C., additional, Joubert, Warren L., additional, Atkinson, Victoria, additional, Mai, Tao, additional, Thomas, Janine M., additional, and Barbour, Andrew P., additional

Published
2018
Full Text
View/download PDF

38. Radiation therapy

Author

Ball, david L. and Burmeister, Bryan H.

Subjects
Lung cancer, Non-small cell -- Care and treatment, Radiotherapy -- Evaluation, Combined modality therapy -- Methods, Health
Abstract

The palliative and therapeutic roles of radiation therapy for non-small-cell lung cancer are presented. Combination therapies may include chemotherapy and radiotherapy for cancers that cannot be surgically treated.

Published
1997

44. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial

Author

Burmeister, Bryan H., primary, Thomas, Janine M., additional, Burmeister, Elizabeth A., additional, Walpole, Euan T., additional, Harvey, Jennifer A., additional, Thomson, Damien B., additional, Barbour, Andrew P., additional, Gotley, David C., additional, and Smithers, B. Mark, additional

Published
2011
Full Text
View/download PDF

50. Combined modality therapy for carcinoma of the oesophagus

Author

Burmeister, Bryan H., Smithers, B. Mark, and Denham, James W.

Subjects
Esophageal cancer -- Care and treatment, Chemotherapy -- Usage, Radiotherapy -- Usage, Squamous cell carcinoma -- Care and treatment, Throat cancer, Cancer -- Adjuvant treatment, Health
Published
1997

Catalog

Books, media, physical & digital resources
See catalog results